Walk the supplement aisle of any pharmacy and you will find probiotic products advertising fifty billion, one hundred billion, or two hundred forty billion CFU. Those numbers are marketing, not science. The research asks one basic question: which specific strain, at which dose, showed a measurable effect in a controlled trial? Labels almost never answer both questions.
What a Probiotic Label Does Not Tell You
The word probiotic describes a category, not a product. A supplement labeled Lactobacillus acidophilus could contain any of dozens of distinct strains, each with different behavior in the gut and a different effective dose. Strain nomenclature has three levels: genus (Lactobacillus), species (acidophilus), and strain designation (DDS-1, NCFM, LA-5). When a label stops at the species level, you cannot use human trial data to evaluate what you are buying.
The NIH Office of Dietary Supplements notes that many commercial probiotic products have not been examined in research studies, and that inconsistent labeling makes it hard to determine which products work. Start by being precise about what the evidence requires.
The Strains With the Strongest Human Evidence
Four strains appear repeatedly in well-designed randomized controlled trials. They are not interchangeable. Their evidence applies to specific outcomes at specific doses, and data for one strain does not transfer to another that shares only a genus name.
Lactobacillus rhamnosus GG (LGG, ATCC 53103)
LGG is among the most researched probiotic strains available, with trials for antibiotic-associated diarrhea, acute gastroenteritis, and gut barrier function. A systematic review of 12 randomized controlled trials and 1,499 participants found that LGG, started within two days of the first antibiotic dose, reduced antibiotic-associated diarrhea to a relative risk of 0.49 (95% CI: 0.29-0.83) compared with placebo - roughly half the observed rate. Three clinical studies showed that 2 x 10^9 CFU per day reduced antibiotic-associated diarrhea. LGG does not have strong evidence for general digestive wellness in healthy adults not taking antibiotics. Its evidence is narrow, its dose is specific, and it should not be used for untested purposes.
Bifidobacterium longum 35624
This strain, formerly classified as B. infantis 35624, has solid human trial data with careful dosing documentation. A randomized, placebo-controlled trial with 362 women with irritable bowel syndrome tested the strain at three doses - 1 x 10^6, 1 x 10^8, and 1 x 10^10 CFU per day - for four weeks. The result was striking: the middle dose of 1 x 10^8 CFU per day worked better than placebo for abdominal pain, bloating, bowel dysfunction, incomplete evacuation, and gas. The lowest and highest doses did not reduce symptoms.
This inverted dose-response curve challenges the assumption that more CFU means more benefit. The strain was later tested at 10^9 CFU per day in a 30-day observational study of 278 adults with IBS, which reduced disease severity, especially in those with the worst baseline symptoms. The takeaway is that each strain has a specific optimal dose based on evidence, not on what the label says.
Saccharomyces boulardii CNCM I-745
Technically a yeast rather than a bacterium, S. boulardii has substantial trial data for antibiotic-associated and infectious diarrhea. A systematic review of 27 randomized placebo-controlled trials with 5,029 patients found that S. boulardii reduced antibiotic-associated diarrhea risk to 0.47 (95% CI: 0.35-0.63). The review showed that results held across different clinical settings and patient populations.
Doses in these trials ranged from 250 mg to 500 mg twice daily, roughly 1 x 10^9 CFU per dose. Study periods ran for the antibiotic course plus one to two weeks. Because S. boulardii is a yeast, antibiotics do not kill it - unlike bacterial strains. This matters when using it alongside antibiotics.
Lactobacillus acidophilus DDS-1
A randomized, double-blind, placebo-controlled trial in 2020 tested this strain alongside Bifidobacterium lactis UABla-12 in adults with irritable bowel syndrome. Participants received 1 x 10^10 CFU per day of either strain alone for six weeks. Both strains reduced abdominal pain compared with placebo, and DDS-1 also improved quality-of-life scores. The trial enrolled 171 participants and used validated symptom tools, making it one of the better-designed probiotic IBS trials published.
The Dose-Response Paradox
This dose-response pattern appears across the probiotic literature. Higher CFU counts do not systematically produce stronger effects. What the research shows is that each strain has a dose range that has been tested, and using doses outside that range is untested. A product advertising 100 billion CFU of a strain whose human trials used 1 x 10^8 CFU does not offer more benefit. It offers an untested dose of a studied strain.
The same applies to multi-strain formulas. The NIH Office of Dietary Supplements found no benefit from multi-strain formulas compared to single strains at their tested doses. Multi-strain formulations may reflect commercial logic more than clinical logic. When a specific combination product has been tested directly, that study applies to that exact combination, not to individual strains in different mixes.
Reading a Label Against the Evidence
Applied to a product in hand, the research above generates four practical questions. First: is the strain identified to the designation level - the genus, species, and alphanumeric code (GG, DDS-1, 35624, CNCM I-745)? Second: does the product dose match the range used in human trials for that strain? Third: does a human controlled trial exist for that strain applied to the outcome you care about, or is it borrowed from a different strain or condition? Fourth: does the product carry a dated certificate of analysis confirming CFU viability from manufacture through consumption, since organisms that die in the bottle cannot work?
If a product passes all four, you have a starting point for comparing it to the published data. If it fails any of these tests, the CFU number on the label does not tell you anything useful. This challenge applies across supplements. As explored in the Ayurnomics Journal piece on collagen and absorption, formulation details determine whether a supplement works the way research showed it could. Probiotics add another variable: viability. A high CFU count at manufacture means nothing if organisms die during storage, shipping, or passage through stomach acid.
For readers interested in how dosing precision affects results across supplement categories, the Journal piece on zinc dosing windows shows how even a well-studied nutrient requires specific timing and doses that labels usually leave out.
What the Evidence Does Not Yet Cover
The four strains reviewed here are the best-studied probiotics for digestive health. They address only some of the claims made by probiotic products. Evidence for probiotics in immune support, mood, skin, and metabolism exists but is preliminary, inconsistent, and strain-specific - not enough to support broad claims. Where those applications interest you, follow the same standard: identify the strain, match the dose to trials, check for independent replication.
If you are exploring gut health and digestive support, the Immunity and Wellness collection includes products with documented strains and doses you can cross-reference against the clinical literature discussed here. More from the science journal follows below.
Vuoi altri contenuti come questo? Unisciti all'Inner Circle e ricevi un articolo curato ogni domenica.